Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Obutinib plus immunochemotherapy for newly diagnosed double expression DLBCL
ChiCTR2600123466Phase 4Recruiting
- Sponsor
- Harbin First Hospital
- Start
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of orelabrutinib in diffuse large B-cell lymphoma (DLBCL), sponsored by Harbin First Hospital. Primary endpoints: Complete remission rate at 3 cycles and end of combination therapy and Overall response rate at 3 cycles and end of combination therapy. Started Apr 2026; status: recruiting.
02
Drugs
orelabrutinib
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on ChiCTR2600123466.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600123466.